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Background  and  purpose:  Octogenarians  (age  ≥ 80  years)  with  coronary  artery  disease  constitute  a high-
risk group.  However,  octogenarian  patients  with  acute  myocardial  infarction  (AMI)  in the drug-eluting
stents  (DES)  era have not  been  widely  reported.  We  aimed  to identify  clinical  outcomes  in octogenarian
compared  with  non-octogenarian  AMI patients.
Methods and subjects:  We  retrospectively  analyzed  9877  patients  who  underwent  percutaneous  coro-vailable online 31 May  2013eywords:
lderly
yocardial infarction
reatment
rognosis
nary  intervention  (PCI)  with  drug-eluting  stents  (DES)  and  who  were  enrolled  in  the  Korean  Acute
Myocardial  Infarction  Registry  (KAMIR).  They  were  divided  into  2 groups,  octogenarians  (n =  1494)  and
non-octogenarians  (n = 8383),  in order  to  compare  the  incidence  of  1-year  all-cause  death  and  1-year
major  adverse  cardiac  events  (MACE),  where  MACE  included  all-cause  death,  recurrent  myocardial  infarc-
tion, target  vessel  revascularization  (TVR),  target  lesion  revascularization  (TLR),  and coronary  artery
bypass grafting  (CABG).
∗ Corresponding author at: Chonnam National University Hospital, 8 Hak-dong, Dong-gu, Gwangju 501-757, Republic of Korea. Tel.: +82 62 220 6243;
ax:  +82 62 228 7174.
E-mail addresses: myungho@chollian.net, myungho@chol.com (M.H. Jeong).
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ttp://dx.doi.org/10.1016/j.jjcc.2013.04.003
F. Yamanaka et al. / Journal of Cardiology 62 (2013) 210–216 211
Results:  The  clinical  status  was  signiﬁcantly  inferior  in octogenarians  compared  to non-octogenarians:
Killip  class  ≥  II (34.8%  vs. 22.5%,  p <  0.001),  multivessel  disease  (65.8%  vs. 53.7%,  p  < 0.001).  Rates  of  1-year
all-cause  death  were  signiﬁcantly  higher  in  octogenarians  than  in non-octogenarians  (22.3%  vs.  6.5%,
p  <  0.001).  However,  the  rates  of  1-year  recurrent  myocardial  infarction  (1.3%  vs.  0.9%,  p  = 0.68),  TLR  (2.4%
vs.  3.1%,  p  =  0.69),  TVR  (3.6%  vs. 4.3%,  p = 0.96),  and  CABG  (0.9%  vs. 0.9%, p = 0.76)  did not  differ  signiﬁcantly
between  the 2 groups.
Conclusions: Octogenarian  AMI  patients  have  higher  rates  of  mortality  and MACE  even  in  the DES era.
According  to KAMIR  subgroup  analysis,  the  TLR/TVR  rates  in  octogenarians  were  comparable  to those  in
non-octogenarian  AMI patients.
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Percutaneous coronary intervention (PCI) has become the
rimary treatment for acute myocardial infarction (AMI) [1]. Fur-
hermore, PCI with drug-eluting stents (DES) has been reported
o markedly reduce the incidence of restenosis and target lesion
evascularization (TLR) [2–5].
The octogenarian population (age ≥ 80 years) is rapidly grow-
ng and these patients are often at the highest risk of procedural
omplications during PCI, owing to their greater prevalence of asso-
iated comorbidities and more depressed cardiac function [6–9].
owever, there are only limited data regarding octogenarian AMI
atients who undergo PCI in the current DES era, because octoge-
arians are less commonly enrolled in randomized clinical trials,
hile observational studies include only a relatively small number
f patients. The aim of this study was to identify the clinical out-
omes in octogenarian AMI  patients who underwent PCI with DES,
ompared with non-octogenarian AMI  patients (age < 80 years).
ethods
tudy population
This study was based on a database collected by the Korean
cute Myocardial Infarction Registry (KAMIR) National Registry
tudy. KAMIR is a prospective, multicenter registry that was
esigned to characterize the clinical features and 1-year prognosis
f AMI in Korean patients. All 51 community and teaching hospi-
als in Korea were invited to participate in KAMIR. A total of 14,885
atients with suspected AMI  at admission were enrolled in KAMIR
rom January 2006 to December 2008.
A total of 9877 consecutive patients who underwent PCI with
ES and whose discharge diagnosis was AMI  were included in the
resent study. The patients were divided into 2 groups: octogenar-
ans (n = 1494, mean age ± 1SD = 84 ± 4 years, range 80–99 years)
nd non-octogenarians (n = 8383, age 63 ± 11 years, range 30–79
ears). An age of 80 years was determined to be an appropriate cut-
ff point, based on a recent report that the event rate is signiﬁcantly
igher in patients aged ≥80 years compared to those aged < 80 years
10].
This analysis compared the following data and endpoints
etween the 2 groups: (1) baseline clinical and angiographic
ndings; (2) 1-year all-cause death; and (3) 1-year major
dverse cardiac events (MACE), including all-cause death, recurrent
yocardial infarction (MI), target vessel revascularization (TVR),
arget lesion revascularization (TLR), and coronary artery bypass
rafting (CABG).
tudy protocol and data collection and managementPatients were enrolled in KAMIR after being admitted to partic-
pating hospitals with a suspected diagnosis of AMI. Detailed data
ere collected at each institution by a study coordinator or doc-
or, who entered the data into a password-protected, web-based,013 Published  by  Elsevier  Ltd on  behalf  of  Japanese  College  of Cardiology.
computerized database provided by the KAMIR committee. Data
coordinators attended meetings at least twice yearly. In addition,
they reviewed and discussed the study protocol.
At participating sites, consecutive patients admitted with AMI
were asked to register for the study. All treatment strategies,
including reperfusion therapy modality and medications, were cho-
sen at the discretion of the attending physicians. This study protocol
was reviewed and approved by the institutional review boards of
the participating centers.
Medical treatment and PCI procedure
All patients received a 300-mg loading dose of aspirin and a
300–600-mg loading dose of clopidogrel and heparin prior to the
procedure. During the procedure, weight-adjusted unfractionated
heparin was administered in a bolus dose of 100 U/kg, with an addi-
tional bolus to maintain an activated clotting time of 250–300 s.
Following the PCI/DES procedure, 100–300 mg/day of aspirin was
continued indeﬁnitely, and 75 mg/day of clopidogrel was continued
for ≥12 months according to guidelines [11,12]. The choice of the
speciﬁc type of DES was left to the operator’s discretion. Coronary
perfusion pre- and post-PCI was  evaluated according to the Throm-
bolysis in Myocardial Infarction (TIMI) perfusion grading system.
Clinical follow up was performed at 1, 6, and 12 months, and when
angina-like symptoms occurred.
Deﬁnitions and clinical endpoints
AMI  was diagnosed according to the European Society of Car-
diology/American College of Cardiology diagnostic criteria [13].
AMI  was diagnosed by characteristic clinical presentation, serial
changes on the electrocardiogram suggesting myocardial infarc-
tion, and elevated cardiac enzymes. ST-segment elevation MI  was
deﬁned as new ST elevation in ≥2 contiguous leads. A history of
hypertension was deﬁned as systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure >90 mmHg at rest on admis-
sion, or treatment with anti-hypertensive medications. Diabetes
mellitus was deﬁned as the use of an oral hypoglycemic agent
or insulin to lower blood glucose levels. Hyperlipidemia was
deﬁned as a total cholesterol level >200 mg/dl or treatment with
a lipid-lowering agent. Coronary artery disease was  deﬁned as a
history of MI,  revascularization procedure, or obstructive coronary
artery disease. Echocardiography was  performed in all patients;
left ventricular ejection fraction was assessed using the modi-
ﬁed Simpson’s biplane method. Recurrent MI  was deﬁned as the
recurrence of symptoms or the presence of electrocardiographic
changes in association with a rise in cardiac biomarker levels above
the upper limit of normal. Death was considered to be cardiac-
related unless non-cardiac death could be deﬁned clearly. The
primary endpoint of this study was  the incidence of all-cause
death, including in-hospital death, at 1 year of follow up. The sec-
ondary endpoint was the 1-year incidence of MACE. The predictors
of all-cause death and MACE at 1 year of follow up were also
investigated.
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Fig. 1. Flowchart illustrating the enrolment of patients in the study. KAMIR, Korean
Acute Myocardial Infarction Registry; AMI, acute myocardial infarction; STEMI,
ST-segment elevation myocardial infarction; NSTEMI, non-ST segment elevation
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tatistical analysis
All eligible patients enrolled in this registry were included in
he analysis. SPSS 18.0 for Windows software (SPSS Inc., Chicago,
L, USA) was used for all analyses. Continuous variables were pre-
ented as mean ± standard deviation and were compared using
tudent’s t-test or the Mann–Whitney U-test. Discrete variables
re presented as counts and percentages, and were compared
sing chi-square statistics or Fisher’s exact test, as appropriate.
tandard statistics were used to describe the baseline clinical and
esion characteristics, and the procedural and clinical outcomes.
ox regression analysis was performed to identify independent
redictors of 1-year mortality and MACE between octogenarian and
on-octogenarian patients. Variables with p < 0.2 in univariate were
ncluded in Cox models.
esults
atients, lesions, and procedural characteristics
The ﬂow chart in Fig. 1 shows the enrolment protocol,
hich resulted in the 2 study groups: octogenarians (n = 1494,
ean age ± 1SD = 84 ± 4 years, range 80–90 years) and non-
ctogenarians (n = 8383, age 63 ± 11 years, range 30–79 years).
The baseline characteristics of the 2 groups are shown in
able 1. Signiﬁcant differences were observed between the 2
roups. Patients in the octogenarian group were more likely to
ave atypical chest pain or painless MI  and were also more likely
o have renal dysfunction (estimated glomerular ﬁltration rate,
FR < 60 ml/min/1.73 m2) and a history of cerebral vascular acci-
ent. The proportion of men  was higher in the non-octogenarian
roup. The prevalence of hypertension was signiﬁcantly higher,
hereas the prevalence of hyperlipidemia, current smoking, and
amily history of coronary artery disease were signiﬁcantly lower
n octogenarians than in non-octogenarians. The clinical condition
as also signiﬁcantly inferior in octogenarians, with lower blood
ressure, lower left ventricular ejection fraction, more frequent
illip class ≥ II (34.8% vs. 22.5%, p < 0.001), higher high-sensitivity
able 1
atient characteristics of octogenarians and non-octogenarians.
Octogenarians (n = 149
Age (years) 84 ± 4 
Male,  n (%) 681 (45.6) 
BMI  (kg/m2) 24 ± 3.2 
History, n (%)
Hypertension 847 (56.7) 
Dyslipidemia 71 (4.8) 
Diabetes mellitus 395 (26.4) 
Smoking 550 (36.8) 
Family history of CAD 39 (3.0) 
Previous coronary interventions 66 (4.4) 
Old  myocardial infarction 59 (3.9) 
Peripheral vascular disease 24 (3.7) 
Cerebral vascular accident 142 (21.7) 
Estimated GFR < 60 (ml/min/1.73 m2), n (%) 674 (45.8) 
Initial  presentation
Atypical symptom, n (%) 274 (18.5) 
Painless myocardial infarction, n (%) 261 (17.6) 
Heart  rate (beats/min) 77 ± 22 
Systolic blood pressure (mmHg) 125 ± 30 
Diastolic blood pressure (mmHg) 75 ± 17 
Killip  class (≥II), n (%) 502 (34.8) 
Peak  troponin I (ng/ml) 49 ± 166 
hs-CRP (mg/dl) 18 ± 66 
NT-proBNP (pg/ml) 4682 ± 7846 
LVEF  < 40%, n (%) 260 (19.8) 
ata are presented as the n (%) of patients or mean ± SD. BMI, body mass index; CAD,
-reactive protein; NT-pro-BNP, N-terminal pro-B type natriuretic peptide; LVEF, left venmyocardial infarction; BMS, bare metal stent; DES, drug-eluting stents.
C-reactive protein (hs-CRP) level (p < 0.001), and higher N-terminal
pro-B-type natriuretic peptide (NT-proBNP) level (p < 0.001). The
rate of ST-segment elevation myocardial infarction (STEMI) and
non-ST-segment elevation myocardial infarction (NSTEMI) was  not
signiﬁcantly different between the groups.
The baseline coronary angiographic observations and proce-
dural outcomes in each group are shown in Table 2. There were
no signiﬁcant differences in the types of culprit lesion between the
2 groups. The octogenarian group exhibited signiﬁcantly more mul-
tivessel disease (65.8% vs. 53.7%, p < 0.001), higher rates of post-PCI
TIMI ﬂow grade 0 or 1 ﬂow (3.8% vs. 2.4%, p = 0.01), and a lower
rate of post-PCI TIMI ﬂow grade 3. In the hospital and at discharge,
octogenarians were less likely to receive evidence-based medical
treatment, including glycoprotein IIb/IIIa inhibitor, aspirin, clopid-
ogrel, -blocker, or statin (p < 0.001).
4) Non-octogenarians (n = 8383) p-Value
63 ± 11 <0.001
6438 (76.9) <0.001
24 ± 3.1 0.436
3880 (46.3) <0.001
859 (10.2) <0.001
2290 (27.3) 0.482
5246 (62.6) <0.001
613 (8.2) <0.001
446 (5.3) 0.147
273 (3.3) 0.171
63 (2.0) 0.011
463 (14.9) <0.001
1879 (22.9) <0.001
1049 (12.6) <0.001
1009 (12.1) <0.001
77 ± 28 0.39
129 ± 33 <0.001
79 ± 26 <0.001
1824 (22.5) <0.001
50 ± 145 0.912
12 ± 51 <0.001
1700 ± 4777 <0.001
1006 (13.3) <0.001
 coronary artery disease; GFR, glomerular ﬁltration rate; hs-CRP, high-sensitivity
tricular ejection fraction.
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Table  2
Characteristics of procedures and medical treatment during hospitalization.
Octogenarians (n = 1494) Non-octogenarians (n = 8383) p-Value
Procedures
STEMI, n (%) 953 (63.8) 5481 (65.4) 0.234
Primary PCI 797 (84.9) 4345 (80.1) 0.001
Facilitated PCI 22 (2.3) 189 (3.5) 0.071
NSTEMI, n (%) 541 (36.2) 2902 (34.6) 0.234
Multivessel PCI, n (%) 348 (24.6) 1842 (23.4) 0.317
Complete revascularization, n (%) 162 (11.4) 1025 (13.0) 0.107
Culprit coronary artery, n (%)
Left main 2 (0.1) 37 (0.5) 0.081
Let  anterior descending 681 (45.9) 3947 (48.5) 0.173
Left  circumﬂex 214 (14.6) 1372 (16.7) 0.045
Right  coronary artery 543 (37.1) 2696 (32.9) 0.002
ACC/AHA typeB2/C, n (%) 1072 (79.2) 5834 (77.0) 0.079
Number of diseased vessels, n (%)
One-vessel disease 477 (32.6) 3657 (44.5) <0.001
Two-vessel disease 488 (33.3) 2558 (31.2) 0.099
Three-vessel disease 462 (31.6) 1805 (22.0) <0.001
Multi-vessel disease 964 (65.8) 4406 (53.7) <0.001
Pre-PCI TIMI 0 or 1, n (%) 812 (58.2) 4399 (56.7) 0.29
Post-PCI TIMI 0 or 1, n (%) 53 (3.8) 180 (2.4) 0.001
Post-PCI TIMI 3, n (%) 1224 (88.6) 7167 (93.7) <0.001
Drug-eluting stent, n (%)
Sirolimus 578 (44.4) 3593 (47.9) 0.018
Paclitaxel 494 (37.9) 2540 (33.9) 0.005
Zotarolimus 133 (10.2) 859 (11.5) 0.189
Other stent 98 (7.5) 507 (6.8) 0.317
Total  number of stents, n (%) 1.6 ± 0.8 1.5 ± 0.8 0.069
Stent  size
Long (mm)  6.0 ± 0.17 6.3 ± 0.07 0.711
Diameter (mm) 3.1 ± 0.4 3.2 ± 0.4 <0.001
Medical treatment, n (%)
Unfractionated heparin 863 (58.2) 4869 (58.4) 0.862
Low  molecular heparin 541 (36.5) 2979 (35.7) 0.59
Glycoprotein IIb/IIIa Inhibitor 185 (12.4) 1341 (16.0) <0.001
Aspirin 1469 (98.3) 8334 (99.4) <0.001
Clopidogrel 1455 (97.4) 8282 (98.8) <0.001
Cilostazol 515 (34.5) 3292 (39.3) <0.001
-Blockers 1057 (70.7) 6638 (79.2) <0.001
ACE-I  1088 (72.8) 6233 (74.4) 0.214
ARB  294 (19.7) 1479 (17.6) 0.059
Statin  1120 (75.0) 6841 (81.6) <0.001
Diuretics 481 (32.2) 2595 (31.0) 0.347
Long-acting nitrates 1130 (75.7) 6154 (73.6) 0.077
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n-hospital events and short-term mortality
There were signiﬁcant differences in in-hospital death, but not
n major bleeding, in the STEMI and NSTEMI groups (Fig. 2).
ne-year outcomes and predictors of major adverse events
Fig. 3A shows the adjusted survival curve for all-cause mortal-
ty. Mortality was higher in the octogenarian group. Age (hazard
atio, HR 2.37, 95% conﬁdence interval, CI 1.56–3.63, p < 0.001),
illip class ≥ II (HR 2.64, 95% CI 1.73–4.05, p < 0.001), STEMI (HR
.74, 95% CI 1.10–2.75, p = 0.018), LVEF < 40% (HR 1.97, 95% CI
.27–3.05, p = 0.002), estimated GFR < 60 ml/min/1.73 m2 (HR 2.33,
5% CI 1.25–4.32, p = 0.008), hs-CRP (HR 1.99, 95% CI 1.25–3.17,
 = 0.004), and NT-proBNP (HR 2.68, 95% CI 1.49–4.83, p = 0.001)
ere independent predictors for 1-year all-cause mortality accord-
ng to multivariable Cox proportional hazard analysis (Table 3).
Fig. 3B shows that the composite MACE outcome was  morerevalent in octogenarians compared with non-octogenarians. Age
HR 1.53, 95% CI 1.16–2.02, p = 0.003), metabolic syndrome (HR
.29, 95% CI 1.04–1.60, p = 0.021), LVEF < 40% (HR 1.88, 95% CI
.45–2.43, p < 0.001), estimated GFR < 60 ml/min/1.73 m2 (HR 1.83,intervention; STEMI, ST segment elevation myocardial infarction; NSTEMI, non-
n; ACC/AHA, American College of Cardiology/American Heart Association; ACE-I,
95% CI 1.18–2.84, p = 0.007), hs-CRP (HR 1.38, 95% CI 1.12–1.72,
p = 0.003), troponin I (HR 1.27, 95% CI 1.03–1.57, p = 0.023), and
multivessel disease (HR 1.60, 95% CI 1.29–2.00, p < 0.001) were
independent predictors for 1-year MACE according to multivariable
Cox proportional hazard analysis (Table 3).
Table 4 shows the clinical outcomes in patients who under-
went primary PCI with DES. The incidence of 1-year cardiac death
and non-cardiac death was signiﬁcantly higher in octogenarians.
There were no signiﬁcant differences in the rate of 1-year recur-
rent myocardial infarction (1.3% vs. 0.9%, p = 0.68), TLR (2.4% vs.
3.1%, p = 0.69), TVR (3.6% vs. 4.3%, p = 0.96), or CABG (0.9% vs.
0.9%, p = 0.76) between the 2 groups. Subgroup analysis by age
demonstrated that an age ≥ 80 years was  associated with 1-year
all-cause death and 1-year MACE, regardless of the subgroup
(Fig. 4). In particular, an age ≥ 80 years in the STEMI subgroup and
the estimated GFR < 60 ml/min/1.73 m2 subgroup was  signiﬁcantly
associated with 1-year all-cause mortality.Discussion
DES have been reported to dramatically reduce the need for
revascularization. However, few reports have described the clinical
214 F. Yamanaka et al. / Journal of Car
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F
ind non-octogenarian patients. STEMI, ST-segment elevation myocardial infarction;
STEMI, non-ST segment elevation myocardial infarction.
mpact of DES in octogenarian AMI  patients. Devlin et al. reported
he management and 6-month outcomes in elderly AMI  patients
rom the Global Registry of Acute Coronary Events (GRACE), but the
ollow-up period of this study was brief [14]. Takii et al. reported the
rends in AMI  incidence and mortality from the MIYAGI-AMI Reg-
stry Study; however, the data obtained did not accurately reﬂect
he actual conditions prevailing during the DES era [15]. Therefore,
he present study can contribute valuable evidence concerning the
rognosis of octogenarian AMI  patients in the DES era.
The ﬁndings reported here revealed the following clinical obser-
ations in the KAMIR subgroup analysis. First, the prevalence of
oncomitant disorders was signiﬁcantly higher in octogenarian
han in non-octogenarian patients. In contrast, octogenarians were
ig. 3. Kaplan–Meier curve with number of patients at risk for octogenarians and non-octog
ncidences of 1-year MACE-free unadjusted survival curves. MACE, major adverse cardiacdiology 62 (2013) 210–216
less likely to receive evidenced-based medical treatment, anti-
platelet therapy, -blockers, and statins. Second, even in the DES
era, there were signiﬁcant differences between the 2 groups in
the occurrence of all-cause death and MACE at 1-year follow up.
However, no signiﬁcant differences in the rate of 1-year recurrent
myocardial infarction, TLR, TVR, recurrent PCI, or CABG were noted
between the 2 groups.
The 1-year rates of overall mortality (8.9%) and MACE (18.5%)
recorded in the present study were roughly consistent with pre-
vious reports. Although octogenarians were more likely to have
complex culprit lesions and multivessel disease, TIMI III ﬂow was
achieved in 88.5% of cases. Nevertheless, octogenarian AMI  patients
had higher 1-year mortality and MACE rates compared with non-
octogenarians, even in the DES era.
Octogenarian AMI  patients, a high-risk population themselves,
may  often not receive appropriate treatment recommended by
current guidelines because of their conditions and comorbidities
[16]. Rittger et al. reported that age was  the main predictor of a
conservative treatment strategy in elderly patients [17]. Medical
treatment was  also likely to be insufﬁcient for elderly patients. Our
study demonstrated that octogenarians were less likely to receive
evidence-based medical therapy, which may  be a possible reason
for the higher incidence of adverse effects or suspected contraindi-
cations of medical therapy.
Apart from age, this study identiﬁed the following variables to be
independent predictors of all-cause death (Killip class ≥ II, STEMI,
LVEF < 40%, estimated GFR < 60 ml/min/1.73 m2, hs-CRP, and NT-
proBNP) and MACE (metabolic syndrome, LVEF < 40%, estimated
GFR < 60 ml/min/1.73 m2, hs-CRP, troponin I, and multivessel dis-
ease) at 1-year follow up. Post-procedural epicardial ﬂow was  not
associated with 1-year mortality in this study. The overall high TIMIIt is well known that elderly MI  patients have a higher risk of
all-cause death and MACE. DES have been reported to dramatically
reduce the rate of restenosis and TLR compared with bare-metal
enarians. (A) 1-Year all-cause death-free unadjusted survival curves. (B) Cumulative
 events.
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Table  3
Multivariate analysis of all-cause death and MACE at 1-year follow-up.
All-cause death MACE
p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI)
Age ≥ 80 <0.001 2.37 (1.56–3.63) 0.003 1.53 (1.16–2.02)
Metabolic syndrome 0.183 1.43 (0.84–2.43) 0.021 1.29 (1.04–1.60)
Killip  class ≥ II <0.001 2.64 (1.73–4.05) 0.149 1.20 (0.94–1.55)
STEMI  0.018 1.74 (1.10–2.75) 0.103 1.23 (0.96–1.57)
Multivessel disease 0.475 1.16 (0.77–1.74) <0.001 1.60 (1.29–2.00)
LVEF  < 40% 0.002 1.97 (1.27–3.05) 0.001 1.88 (1.45–2.43)
TnI  0.137 1.37 (0.90–2.11) 0.048 1.27 (1.03–1.57)
Estimated GFR < 60 0.008 2.33 (1.25–4.32) 0.042 1.83 (1.18–2.84)
hs-CRP  0.004 1.99 (1.25–3.17) 0.017 1.38 (1.12–1.72)
NT-proBNP 0.001 2.68 (1.49–4.83) 0.515 1.09 (0.85–1.39)
MACE, major adverse cardiac event; STEMI, ST segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; TnI, troponin I; GFR, glomerular ﬁltration
rate;  hs-CRP, high-sensitivity C-reactive protein; NT-pro-BNP, N-terminal pro-B type natriuretic peptide; CI, conﬁdence interval.
Table  4
Adjusted cumulative clinical outcomes at 1 year.
Octogenarians n (%) Non-octogenarians n (%) Unadjusted HR (95% CI) p-Value Adjusted HR (95% CI) p-Value
All-cause death 223 (22.3) 359 (6.5) 3.75 (3.17–4.43) <0.001 2.37 (1.56–3.63) <0.001
Cardiac death 194 (19.4) 319 (5.8) 3.62 (3.03–4.33) <0.001 3.03 (2.20–4.17) <0.001
Non-cardiac death 29 (2.9) 40 (0.7) 4.65 (2.88–7.50) <0.001 5.68 (2.87–11.2) <0.001
Recurrent MI  13 (1.3) 52 (0.9) 1.59 (0.86–2.91) 0.14 1.19 (0.52–2.72) 0.68
Recurrent PCI 57 (5.7) 469 (8.5) 0.79 (0.60–1.04) 0.09 0.84 (0.61–1.17) 0.31
TLR  24 (2.4) 170 (3.1) 0.92 (0.60–1.40) 0.69 0.89 (0.52–1.54) 0.69
TVR  36 (3.6) 236 (4.3) 0.99 (0.70–1.41) 0.96 0.99 (0.64–1.54) 0.96
CABG  9 (0.9) 51 (0.9) 1.08 (0.53–2.20) 0.83 0.83 (0.24–2.80) 0.76
MACE  296 (29.6) 909 (16.4) 2.03 (1.78–2.31) <0.001 1.53 (1.16–2.02) 0.003
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Gata are presented as the n (%) of patients or mean ± SD. HR, hazard ratio; MI,  myo
ization; TVR, target vessel revascularization; CABG, coronary artery bypass graftin
tents (BMSs) [18–20]. In contrast, PCI with DES might be asso-
iated with an increase in the rate of stent thrombosis because
f the delayed arterial healing response [21,22]. Stent thrombo-
is is an unusual, but life-threatening complication associated with
ES implantation. Spaulding et al. reported that there was  no
ig. 4. Estimates of hazard ratios in selected subgroups. Hazard ratios are shown
n  a logarithmic scale. (A) All-cause death at 1-year follow up. (B) Major adverse
ardiac events at 1-year follow up. HR, hazard ratio; STEMI, ST-segment elevation
yocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction;
FR, glomerular ﬁltration rate; LVEF, left ventricular ejection fraction.l infarction; PCI, percutaneous coronary intervention; TLR, target lesion revascula-
CE, major adverse cardiac events.
difference in the rate of stent thrombosis at 1-year follow up among
AMI  patients; furthermore, the use of DES signiﬁcantly reduced the
rate of TVR [23]. Violini et al. found that the 3-year incidence of
MACE, and of TLR and TVR, was  lower in the DES (sirolimus-eluting
stent) group compared with the BMS  group [24]. The present study
did not provide follow-up data for stent thrombosis according to
the ARC deﬁnition.
Elderly patients receiving dual anti-platelet therapy represent
a high-risk group for bleeding [25]. However, the data from this
registry showed no signiﬁcant difference in the occurrence of
in-hospital major bleeding between the 2 groups. The discrep-
ancy could be attributable to the relatively low use of antiplatelet
therapy and the short follow-up period. The present study did
not include long-term follow up of major bleeding data. The
new-generation DES are reported to reduce the duration of dual
anti-platelet therapy without increasing the risk of stent throm-
bosis [26]. Further study is required to identify long-term major
bleeding and optimal anti-platelet therapy for octogenarians.
Subgroup analysis identiﬁed that an age ≥ 80 years was asso-
ciated with 1-year all-cause death and MACE regardless of the
subgroup. Furthermore, in the subgroups with STEMI or estimated
GFR < 60 ml/min/1.73 m2, age ≥ 80 years was  strongly associated
with all-cause death. These data were consistent with previous
reports from the BMS  era. This study was retrospective, but pro-
vided a sufﬁcient number of patients to investigate the predictors of
all-cause death and MACE at 1 year of follow up. Octogenarians are
usually not included in randomized studies; therefore, this study
describes the real-world outcomes of octogenarians undergoing PCI
in the DES era.
There are few reports regarding octogenarian AMI  patients
after the use of DES. The results of our study suggested there
was no difference in TLR/TVR rates between octogenarians and
non-octogenarians. Considering the risks and beneﬁts of PCI for
octogenarian AMI  patients, PCI with DES might be a comparable
therapeutic option.
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This study had some limitations. First, it was based on registry
ata, and such studies are always affected by unavoidable selec-
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nvolved a prospective design and a large multicenter population
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reater comorbidities and a signiﬁcantly higher incidence of all-
ause death and MACE, even in the DES era. However, KAMIR
ubgroup analysis revealed no difference in TLR/TVR rates between
he 2 groups.
cknowledgments
This study was supported by a grant from the Korea Healthcare
echnology R&D Project, Ministry for Health, Welfare, and Family
ffairs (A084869). This study was performed with the support of
he Korean Society of Circulation (KCS) as the memorandum of the
0th Anniversary of the KCS.
eferences
[1] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm-
bolytic therapy for acute myocardial infarction: a quantitative review of 23
randomised trials. Lancet 2003;361:13–20.
[2] Moses JW,  Leon MB,  Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy
C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE.
Sirolimus-eluting stents versus standard stents in patients with stenosis in a
native coronary artery. N Engl J Med  2003;349:1315–23.
[3] Morice MC,  Serruys PW,  Sousa JE, Fajadet J, Ban Hayashi E, Perin M,  Colombo
A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R. A randomized
comparison of a sirolimus-eluting stent with a standard stent for coronary
revascularization. N Engl J Med  2002;346:1773–80.
[4] Schofer J, Schluter M,  Gershlick AH, Wijns W,  Garcia E, Schampaert E, Breithardt
G.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic
lesions in small coronary arteries: double-blind, randomised controlled trial
(E-SIRIUS). Lancet 2003;362:1093–9.
[5] Schampaert E, Cohen EA, Schluter M,  Reeves F, Traboulsi M, Title LM,  Kuntz RE,
Popma JJ. The Canadian study of the sirolimus-eluting stent in the treatment of
patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
J  Am Coll Cardiol 2004;43:1110–5.
[6] De Gregorio J, Kobayashi Y, Albiero R, Reimers B, Di Mario C, Finci L, Colombo
A. Coronary artery stenting in the elderly: short-term outcome and long-term
angiographic and clinical follow-up. J Am Coll Cardiol 1998;32:577–83.
[7] DeGeare VS, Stone GW,  Grines L, Brodie BR, Cox DA, Garcia E, Wharton TP, Boura
JA,  O’Neill WW,  Grines CL. Angiographic and clinical characteristics associated
with increased in-hospital mortality in elderly patients with acute myocar-
dial  infarction undergoing percutaneous intervention (a pooled analysis of the
primary angioplasty in myocardial infarction trials). Am J Cardiol 2000;86:
30–4.
[8] Lindsay Jr J, Reddy VM,  Pinnow EE, Little T, Pichard AD. Morbidity and mortal-
ity  rates in elderly patients undergoing percutaneous coronary transluminal
angioplasty. Am Heart J 1994;128:697–702.
[9] Santana JO, Haft JI, LaMarche NS, Goldstein JE. Coronary angioplasty in patients
eighty years of age or older. Am Heart J 1992;124:13–8.
10] Hong YJ, Jeong MH,  Abizaid A, Banning A, Bartorelli A, Dzavik V, Ellis SG, Gao
R,  Holmes Jr DR, Legrand V, Neumann FJ, Spaulding C, Worthley S, Urban P.
[diology 62 (2013) 210–216
e-SELECT Registry Investigators. Sirolimus-eluting coronary stents in octoge-
narians: a 1-year analysis of the worldwide e-SELECT Registry. JACC Cardiovasc
Interv 2011;4:982–91.
11] Kushner FG, Hand M,  Smith Jr SC, King 3rd SB, Anderson JL, Antman EM,  Bai-
ley SR, Bates ER, Blankenship JC, Casey Jr DE, Green LA, Hochman JS, Jacobs
AK, Krumholz HM, Morrison DA, et al. 2009 Focused updates: ACC/AHA guide-
lines for the management of patients with ST-elevation myocardial infarction
(updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI
guidelines on percutaneous coronary intervention (updating the 2005 guide-
line and 2007 focused update): a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines. Cir-
culation 2009;120:2271–306.
12] Hamm CW,  Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek
D,  Gielen S, Huber K, Ohman M,  Petrie MC,  Sonntag F, Uva MS,  Storey RF, et al.
ESC guidelines for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation: the Task Force for the
management of acute coronary syndromes (ACS) in patients presenting with-
out persistent ST-segment elevation of the European Society of Cardiology
(ESC). Eur Heart J 2011;32:2999–3054.
13] Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College
of  Cardiology guidelines for redeﬁnition of myocardial infarction: how to use
existing assays clinically and for clinical trials. Am Heart J 2002;144:981–6.
14] Devlin G, Gore JM, Elliott J, Wijesinghe N, Eagle KA, Avezum A, Huang
W,  Brieger D. GRACE Investigators. Management and 6-month outcomes in
elderly and very elderly patients with high-risk non-ST-elevation acute coro-
nary syndromes: the Global Registry of Acute Coronary Events. Eur Heart J
2008;29:1275–82.
15] Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, Shimokawa H. MIYAGI-
AMI  Study Investigators. Trends in acute myocardial infarction incidence and
mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study.
Circulation 2010;74:93–100.
16] Wijns W,  Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K,
James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M,  Piepoli MF,
et  al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501–55.
17] Rittger H, Schnupp S, Sinha AM,  Breithardt OA, Schmidt M,  Zimmermann S,
Mahnkopf C, Brachmann J, Rieber J. Predictors of treatment in acute coronary
syndromes in the elderly: impact on decision making and clinical outcome
after interventional vs. conservative treatment. Catheter Cardiovasc Interv
2012;80:735–43.
18] Kelbaek H, Helqvist S, Thuesen L, Klovgaard L, Jorgensen E, Saunamaki K, Krusell
LR, Bøtker HE, Engstrøm T, Jensen GV. Sirolimus versus bare metal stent implan-
tation in patients with total coronary occlusions: subgroup analysis of the
Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT)
trial. Am Heart J 2006;152:882–6.
19] Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky
RL,  Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD,  Kelsey
SF,  Kip KE. A comparison of bare-metal and drug-eluting stents for off-label
indications. N Engl J Med 2008;358:342–52.
20] Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC,  Schomig A, Pﬁsterer
ME,  Stone GW,  Leon MB,  de Lezo JS, Goy JJ, Park SJ, Sabaté M,  Suttorp MJ,  Kel-
baek  H, et al. Outcomes associated with drug-eluting and bare-metal stents: a
collaborative network meta-analysis. Lancet 2007;370:937–48.
21] Nakazawa G. Stent thrombosis of drug eluting stent: pathological perspective.
J  Cardiol 2011;58:84–91.
22] Takayama T, Hiro T, Hirayama A. Stent thrombosis and drug-eluting stents. J
Cardiol 2011;58:92–8.
23] Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely
B,  Erglis A, Margheri M,  Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C.
Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl
J  Med  2006;355:1093–104.
24] Violini R, Musto C, De Felice F, Nazzaro MS,  Cifarelli A, Petitti T, Fiorilli R. Main-
tenance of long-term clinical beneﬁt with sirolimus-eluting stents in patients
with ST-segment elevation myocardial infarction 3-year results of the SESAMI
(sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction)
trial. J Am Coll Cardiol 2010;55:810–4.
25] Bhatt DL, Fox KA, Hacke W,  Berger PB, Black HR, Boden WE,  Cacoub P, Cohen EA,
Creager MA, Easton JD, Flather MD,  Haffner SM, Hamm CW,  Hankey GJ, Johnston
SC, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of
atherothrombotic events. N Engl J Med  2006;354:1706–17.
26] Damman P, Iniguez A, Klomp M,  Beijk M,  Woudstra P, Silber S, Ribeiro EE,
Suryapranata H, Sim KH, Tijssen JG, de Winter RJ. e-HEALING investigators.
Coronary stenting with the Genous Bio-Engineered R Stent in elderly patients.
Circ J 2011;75:2590–7.
